Trial Profile

Phase I/II Trial of the Addition of PD 0332991 to Cetuximab in Patients With Incurable SCCHN

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 27 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cetuximab (Primary) ; Palbociclib (Primary)
Indications Head and neck cancer; Squamous cell cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

20 Dec 2023 Status changed from active, no longer recruiting to completed.
03 Nov 2023 Planned End Date changed from 9 Apr 2025 to 31 Oct 2024.
17 May 2021 Planned End Date changed from 31 Oct 2024 to 9 Apr 2025.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com